Given the pivotal role of immunity in the initiation and progression of tumors demonstrated in recent studies, immunotherapy represented by PD-1/PD-L1 inhibitors (3) has provided novel choices for the treatment of glioma. The gene discussed is PDCD1; the disease is glioma.